Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

First-Line Acalabrutinib Plus BR Receives CHMP Recommendation for Mantle Cell Lymphoma

March 31st 2025

CHMP recommends EU approval of acalabrutinib plus chemoimmunotherapy for untreated mantle cell lymphoma.

Dr Fenske on the Benefit With Auto-HSCT in MRD-Positive Patients With MCL in First CR

March 21st 2025

Timothy S. Fenske, MD, MS, discusses survival outcomes in patients with MCL who remained MRD positive following consolidative auto-HCT.

7-Year Data Show Feasibility of Elective Treatment Interruption of Venetoclax/Ibrutinib in R/R MCL

March 14th 2025

Patients with relapsed/refractory MCL who opted for elective treatment interruptions from venetoclax/ibrutinib experienced durable responses.

Dr Phillips on Future Avenues for Improving the Management of High-Risk MCL

March 13th 2025

Tycel J. Phillips, MD, MPH, discusses the need for more large, randomized clinical trials enrolling patients with high-risk MCL.

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL

March 13th 2025

Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.

Dr Dreyling on the Rationale Behind the TRIANGLE Study in MCL

March 12th 2025

Martin Dreyling, MD, discusses the rationale for evaluating the addtion of ibrutinib to chemoimmunotherapy and ASCT in mantle cell lymphoma.

BOVen Regimen Is Safe and Effective in First-Line TP53-Mutated MCL

March 11th 2025

BOVen met the primary end point of 2-year PFS in a phase 2 study, displaying high response rates in treatment-naive TP53-mutated MCL.

Acalabrutinib Plus Bendamustine and Rituximab Displays Long-Term Activity in Frontline and R/R MCL

March 11th 2025

Acalabrutinib plus BR showed OS and PFS efficacy with a tolerable safety profile with long-term follow-up in first-line and R/R MCL.

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL

February 25th 2025

At 5 years of follow-up, sustained disease control was demonstrated with ibrutinib plus venetoclax and obinutuzumab in patients with newly diagnosed MCL.

Dr Dreyling on Safety Data With ASCT Plus Ibrutinib and Rituximab in Lower-Risk, Younger MCL

February 21st 2025

Martin Dreyling, MD, discusses updated safety results from the randomized phase 3 TRIANGLE trial in younger patients with lower-risk MCL.

Zilovertamab Vedotin Produces Activity in Heavily Pretreated R/R Mantle Cell Lymphoma

February 11th 2025

Zilovertamab vedotin generated responses and was safe in heavily pretreated relapsed/refractory mantle cell lymphoma.

Alisertib Plus Ibrutinib and Rituximab Shows Preclinical Efficacy in MCL Models

February 10th 2025

Alisertib plus ibrutinib and rituximab showed anti-tumor activity in mantle cell lymphoma in a preclinical study.

Acalabrutinib Plus Venetoclax/Obinutuzumab Demonstrates Efficacy, Safety in Mantle Cell Lymphoma

February 10th 2025

Acalabrutinib plus venetoclax and obinutuzumab demonstrated antitumor activity with a manageable safety profile in mantle cell lymphoma.

Dr Fenske on the Rationale of Assessing Rituximab With or Without ASCT in MRD-Negative MCL

February 6th 2025

Timothy S. Fenske, MD, MS, details the rationale of a phase 3 trial assessing rituximab with or without ASCT in mantle cell lymphoma.

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

February 4th 2025

Tom van Meerten, MD, PhD, discusses the role of brexucabtagene autoleucel in high-risk MCL.

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

February 3rd 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Dr Dreyling on the Potential for Chemotherapy-Free Treatments in MCL

January 29th 2025

Martin Dreyling, MD, discusses ongoing trials exploring chemotherapy-free strategies in mantle cell lymphoma using BTK inhibitors.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

Dr Phillips on the Rationale of Evaluating Glofitamab in R/R Mantle Cell Lymphoma

January 17th 2025

Tycel Phillips, MD, MPH, discusses the rationale of the phase 1/2 NP30179 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.